Rango de valoración compuesto · conservador HK$3.8–HK$4.1 / razonable HK$6.3–HK$8.5 / optimista HK$11.6–HK$13. A HK$7.17, Dentro del rango de valor intrínseco razonable.
Al publicar HK$6.96 (24 de junio de 2026)
XtalPi said its AI autonomous materials-characterization workstation with Sinopec Shanghai Research Institute and JWGB entered operation.
Possible impact:May affect expectations for commercialization of its AI-for-Science materials R&D platform.
XtalPi announced a more than $400 million AI drug-discovery collaboration with an international biopharma company on a GPCR target.
Possible impact:May affect revenue visibility and expectations for monetization of its AI drug-discovery platform.
XtalPi said its AI-designed oral peptide ingredient Tensotide received U.S. self-affirmed GRAS status.
Possible impact:May affect expectations for commercialization in consumer-health ingredients.
XtalPi said its DoveTree oncology program advanced to IND-enabling studies and it received a $19 million second payment.
Possible impact:May affect expectations for execution of the up-to-$5.99 billion DoveTree collaboration.
XtalPi reported 2025 revenue of RMB802.6 million, up 201.2%, and annual profit of RMB134.6 million.
Possible impact:May affect expectations for growth quality, profitability inflection and valuation support.
Automatically summarized from public sources; for context only, not investment advice.
Datos de EODHD, mostrados en la moneda de reporte; solo a título informativo, no constituye asesoramiento de inversión.
XtalPi Holdings Limited operates as a research platform company in Mainland China, the United States, and internationally. The company offers XmartChem, an intelligent synthesis workstation which automates the chemical synthesis process; ChemPlus, desktop solid dispensing device; PatSight, an optical chemical structure extraction tool for patents; and XFEP, a software for rapid FEP calculations using cloud computing. It also provides XMolGen, a generative chemistry tool; and drug discovery solutions, such as hit discovery, hit or lead optimization, and biology capabilities, as well as PepiX, which generates stable peptides. In addition, the company offers discovery chemistry solutions, including automation-aided chemical synthesis and focused library; and XtalGazer, a solid-state research solution. It has a strategic collaboration with Pfizer to co-build an AI-driven molecular simulation research and development platform; and DoveTree to develop therapeutics designed for multiple difficult-to-drug targets. The company was formerly known as QuantumPharm Inc. and changed its name to XtalPi Holdings Limited in December 2024. XtalPi Holdings Limited was founded in 2015 and is headquartered in Shenzhen, China.
PróximamenteEsta sección se está completando; vuelve pronto.
PróximamenteEsta sección se está completando; vuelve pronto.
Aún no hay análisis sobre este valor en tu idioma.